ENPP2;ATX;PDNP2

Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (E-NPP 2) (EC 3.1.4.39) (Autotaxin) (Extracellular lysophospholipase D) (LysoPLD)

Homo sapiens (Human)

98994

863

Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (E-NPP 2) (EC 3.1.4.39) (Autotaxin) (Extracellular lysophospholipase D) (LysoPLD)

UP000005640

MARRSSFQSCQIISLFTFAVGVNICLGFTAHRIKRAEGWEEGPPTVLSDSPWTNISGSCKGRCFELQEAGPPDCRCDNLCKSYTSCCHDFDELCLKTARGWECTKDRCGEVRNEENACHCSEDCLARGDCCTNYQVVCKGESHWVDDDCEEIKAAECPAGFVRPPLIIFSVDGFRASYMKKGSKVMPNIEKLRSCGTHSPYMRPVYPTKTFPNLYTLATGLYPESHGIVGNSMYDPVFDATFHLRGREKFNHRWWGGQPLWITATKQGVKAGTFFWSVVIPHERRILTILQWLTLPDHERPSVYAFYSEQPDFSGHKYGPFGPEMTNPLREIDKIVGQLMDGLKQLKLHRCVNVIFVGDHGMEDVTCDRTEFLSNYLTNVDDITLVPGTLGRIRSKFSNNAKYDPKAIIANLTCKKPDQHFKPYLKQHLPKRLHYANNRRIEDIHLLVERRWHVARKPLDVYKKPSGKCFFQGDHGFDNKVNSMQTVFVGYGSTFKYKTKVPPFENIELYNVMCDLLGLKPAPNNGTHGSLNHLLRTNTFRPTMPEEVTRPNYPGIMYLQSDFDLGCTCDDKVEPKNKLDELNKRLHTKGSTEERHLLYGRPAVLYRTRYDILYHTDFESGYSEIFLMPLWTSYTVSKQAEVSSVPDHLTSCVRPDVRVSPSFSQNCLAYKNDKQMSYGFLFPPYLSSSPEAKYDAFLVTNMVPMYPAFKRVWNYFQRVLVKKYASERNGVNVISGPIFDYDYDGLHDTEDKIKQYVEGSSIPVPTHYYSIITSCLDFTQPADKCDGPLSVSSFILPHRPDNEESCNSSEDESKWVEELMKMHTARVRDIEHLTSLDFFRKTSRSYPEILTLKTYLHTYESEI

Active site (1); Alternative sequence (2); Beta strand (32); Binding site (2); Chain (1); Disulfide bond (15); Domain (2); Glycosylation (4); Helix (43); Metal binding (12); Motif (1); Mutagenesis (6); Natural variant (3); Propeptide (1); Region (3); Sequence conflict (24); Signal peptide (1); Site (1); Turn (9),N/A,Up-regulated in massively obese subjects with glucose intolerance, and during adipogenesis. {ECO:0000269|PubMed:15700135}.,Detected in blood plasma (at protein level) (PubMed:12176993, PubMed:26371182). Predominantly expressed in brain, placenta, ovary, and small intestine. Expressed in a number of carcinomas such as hepatocellular and prostate carcinoma, neuroblastoma and non-small-cell lung cancer. Expressed in body fluids such as plasma, cerebral spinal fluid (CSF), saliva, follicular and amniotic fluids. Not detected in leukocytes. Isoform 1 is more highly expressed in peripheral tissues than in the central nervous system (CNS). Adipocytes only express isoform 1. Isoform 3 is more highly expressed in the brain than in peripheral tissues. {ECO:0000269|PubMed:12176993, ECO:0000269|PubMed:18175805, ECO:0000269|PubMed:26371182, ECO:0000269|PubMed:8579579, ECO:0000269|PubMed:8586446}.,H2O [CHEBI:15377]; Zn(2+) [CHEBI:29105]; H(+) [CHEBI:15378]; ethanolamine [CHEBI:57603]; Ca(2+) [CHEBI:29108]; 1-O-alkyl-sn-glycero-3-phosphoethanolamine [CHEBI:76168]; 1-O-alkyl-sn-glycero-3-phosphate [CHEBI:58014],H2O [CHEBI:15377]; H(+) [CHEBI:15378]; ethanolamine [CHEBI:57603]; 1-O-alkyl-sn-glycero-3-phosphoethanolamine [CHEBI:76168]; 1-O-alkyl-sn-glycero-3-phosphate [CHEBI:58014],Zn(2+) [CHEBI:29105]; Ca(2+) [CHEBI:29108],N/A

Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (E-NPP 2) (EC 3.1.4.39) (Autotaxin) (Extracellular lysophospholipase D) (LysoPLD)

Recombinant

94.5 kDa

HEK293

Human

Lyophilized

7.4-7.5

Sterile-filtered colorless solution

1mg/ml

Standard

PBS

> 98%

SDS-PAGE

RP-HPLC

-20°C

This bioreagent is stable at 4°C (short-term) and -70°C(long-term). After reconstitution, sample may be stored at 4°C for 2-7 days and below -18°C for future use.

Reconstitute in sterile distilled H2O to no less than 100ug/ml; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.